Fast Five Quiz: Multiple Myeloma Management

Joshua Richter, MD; Emmanuel C. Besa, MD


January 11, 2022

The CD38 molecule is highly expressed on the surface of multiple myeloma cells; therefore, it is a target of certain novel monoclonal antibodies used in the treatment of multiple myeloma.

Mutations in BRCA1 are targets in breast cancer, ovarian cancer, and prostate cancer. The CD20 molecule is a target for B-cell malignant tumors, as well as for leukemias and lymphomas, and the CD30 molecule is a target for some lymphomas.

Learn more about monoclonal antibodies in multiple myeloma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.